Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
lung fibrosis; high serum levels associated with less severe disease in rheumatoid arthritis patients
Modality
Monoclonal Antibody
Mechanism
anti-PAD4 monoclonal antibody
Target
PADI4
rNPV Envelope
Low
-$20.6M
costs +25% · peak −25%
Base
$27.8M
cumulative PoS 7.0%
High
$76.3M
costs −25% · peak +25%
Costs follow biologic CMC norms with elongated late-stage development to reflect lung-fibrosis FVC-decline endpoints (Ofev/Esbriet pivotal trials ran 52 weeks plus open-label extensions; PF-ILD adjudication adds duration). Phase 1 PoS uses RA mAb baselines; Phase 2 is held to BIO/QLS RA-mAb levels with a small downward adjustment because the agonistic monocyte-activating mechanism is unprecedented in a therapeutic mAb and increases proof-of-concept risk in patients. Phase 3 PoS reflects RA-biologic precedent narrowed to the RA-ILD subset, where the disease-modifying endpoint history is mixed (RECITAL was non-superior vs cyclophosphamide).
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.60
Modality fit · 30%
0.90
Whitespace · 30%
0.50
Composite 0.660 — composite-score rank #11 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#2) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Rituxan / MabThera (Genentech/Roche) — rituximab
Approved RA biologic with robust off-label evidence (RECITAL Phase 2b RCT and meta-analyses) for RA-ILD lung-function stabilization; sets the realistic upper bound for any new RA-ILD-focused biologic.
Criteria 2 and 4: launched RA mAb comparator and the de-facto biologic standard for RA-ILD rescue therapy; pre-biosimilar peak anchors RA-biologic revenue ceiling.
Ofev (Boehringer Ingelheim) — nintedanib
Approved oral antifibrotic for IPF, SSc-ILD, and PF-ILD (which includes RA-ILD); demonstrates the regulatory and commercial pathway for slowing FVC decline in fibrotic lung disease.
Criteria 2 and 3: launched lung-fibrosis comparator anchoring pivotal-trial endpoints (FVC decline) and durable multi-billion-dollar antifibrotic revenue.
Esbriet (Roche/Genentech) — pirfenidone
Cautionary launched-and-eroded antifibrotic precedent: blockbuster trajectory through 2021 then rapid generic erosion; demonstrates the LOE risk for any small-molecule antifibrotic but matters less for a biologic with longer effective exclusivity.
Criteria 2 and 4: launched lung-fibrosis comparator with full launch-to-generic-erosion arc; sets the lower bound for branded antifibrotic peak.
JBI-589 / JBI-1044 (Jubilant Therapeutics) — selective PAD4 small-molecule inhibitor program
Closest active PAD4-mechanism program; preclinical RA efficacy with selective oral inhibition. Reads the opposite mechanistic direction (enzyme inhibition vs the asset's activating monocyte agonism) and frames the competitive landscape for any PAD4-targeting agent.
Criteria 1: same molecular target (PAD4) but inverse mechanism. Provides the IP and timing context for the PAD4-target class even though the JHU asset is a monoclonal antibody.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $18.0M | 24 mo | 50.0% | [0] [4] [5] |
| Phase I | $55.0M | 18 mo | 66.0% | [0] [1] [5] |
| Phase II | $160.0M | 30 mo | 40.0% | [1] [2] [5] |
| Phase III | $340.0M | 42 mo | 60.0% | [1] [2] [3] [5] |
| NDA/BLA Review | $15.0M | 12 mo | 88.0% | [2] [3] [5] |
Multiplier handling: Eligible multipliers (biomarker_1.7x, fast_track_or_rmat) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$1.30B peak · WACC 13.0%
Peak revenue. RA-ILD is roughly 5-10% of the ~1.3M US RA population, with global addressable patient counts on the order of 1-2 million. At biologic pricing of $25-50K per patient-year, the addressable revenue ceiling for a successful RA-ILD-only mAb is $1.5-3B before share assumptions; $1.3B reflects realistic Year-7 share against off-label rituximab and antifibrotic standard of care, with optionality for IPF or SSc-ILD label expansion if the mechanism translates beyond the RA-anti-PAD4-positive subset. Modeled below Ofev's $3.8B peak because Ofev addresses three indications where this asset would launch in one biomarker-defined subset.
WACC. RA biologic in a biomarker-stratified subset is a mainstream pharma category, but the agonistic-antibody mechanism is unprecedented and competing PAD4-inhibitor and BMS PAD4-mAb programs add competitive risk. The 13% sits between standard-RA-biologic risk (12%) and CNS biologic risk (14%).
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV ($27.8M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$237.9M
P25
-$96.1M
P50 (median)
-$24.1M
P75
-$11.2M
P95
$1.16B
Prob ≥ 0
7.4%
Comparable launch curves
Revenue trajectories of named comparators
Rituxan / MabThera (Genentech/Roche) — rituximab
Launched 1997 · peak $7.13B (estimated)
Evidence register
6 per-assumption citations
Thesis
Why this asset earns its rank
The anti-PAD4 monoclonal antibody asset is mechanistically unusual: it is an agonistic biologic, not an enzyme blocker. Wilson 2023 from the same Hopkins group shows that RA patients with serum anti-PAD4 antibodies have less lung fibrosis, better preserved FVC, and lower mortality, and the patent's preclinical data argue that the antibody hyperactivates a monocyte pro-inflammatory and TNF-secreting program that paradoxically resolves established lung fibrosis. The top-10 ranking is driven by clinical relevance in RA-ILD, a clean biomarker-defined patient subset, and high IRA exposure for an RA biologic.
Comparator economics are well-anchored. Rituxan demonstrates RA-mAb pre-biosimilar peak and is the off-label biologic most often used as RA-ILD rescue (RECITAL Phase 2b, NCT01862926). Ofev frames lung-fibrosis pivotal-trial design and durable multi-billion-dollar antifibrotic revenue, while Esbriet's launch-to-generic-erosion arc bounds antifibrotic LOE risk. Jubilant's PAD4 inhibitor program is the IP-and-timing comparator for the broader PAD4 target class. The engine result is -$20.6M to $76.3M, with a base rNPV of $27.8M and cumulative PoS of 7.0%; that supports the VC-fundable archetype if the first program tightly enrolls anti-PAD4-positive RA-UIP patients rather than chasing the full RA market.
The verdict is a credible but mechanism-defensibility-heavy investment. It earns its top-10 slot because the biology is biomarker-anchored and the unmet need is severe, but the funding case depends on showing that an agonistic anti-PAD4 antibody can produce monocyte activation profiles that translate into fibrosis resolution in patients, not only in the Wilson 2023 observational cohort and animal models.
Key risks
Asset-specific, not generic biotech risks
- The therapeutic mechanism is agonistic monocyte activation rather than enzyme inhibition; this is unprecedented for a marketed mAb and increases proof-of-concept risk vs the same group's prior work showing anti-PAD4 antibodies drive arthritogenic monocyte hyperactivation.
- BMS holds a competing PAD4-targeting program (recent 2025 patent disclosure following the Padlock acquisition) and Jubilant Therapeutics has an active oral PAD4 inhibitor pipeline, creating crowded IP and timing pressure.
- RA-ILD pivotal trials are long and large because FVC decline endpoints accumulate slowly; RECITAL's non-superior rituximab-versus-cyclophosphamide outcome shows how easily a CTD-ILD biologic can fail to differentiate.
- The RA biologic market is dominated by anti-TNF, JAK inhibitors, and rituximab biosimilars, all priced down by competition; commercial pricing power for an RA-ILD-only biologic depends on credible disease-modifying differentiation rather than parity with off-label rituximab.